ALX Oncology (ALXO) Study Update summary
Event summary combining transcript, slides, and related documents.
Study Update summary
8 Jul, 2026Study background and design
Evaluated evorpacept, a CD47 blocker, in combination with zanidatamab, a bispecific HER2-targeted antibody, in metastatic breast cancer patients who were heavily pretreated, including prior T-DXd/Enhertu exposure.
Phase 1b/2 trial included HER2-positive, HER2-low, and non-breast HER2-expressing tumor cohorts, focusing on unresectable, locally advanced, or metastatic cancers.
Patients in the HER2-positive cohort had received a median of 6 prior therapies; all had at least three prior regimens, reflecting high unmet need.
Central confirmation of HER2 status was required when feasible, highlighting tumor heterogeneity.
The combination aims to provide a chemotherapy-free regimen for heavily pretreated patients, addressing limited post-Enhertu options.
Key efficacy and safety results
In centrally confirmed HER2-positive breast cancer, ORR/CORR was 55–55.6%, disease control rate was 77.8–80%, and median PFS was 7.4 months.
HER2-low cohort showed a 20% ORR/CORR and DCR of 40%, with PFS comparable to other post-T-DXd regimens.
Responses were durable, with several patients on therapy for over 6 and 12 months; 71% of HER2-positive patients had target lesion reduction.
Safety profile was favorable; most TRAEs were grade 1 or 2, with manageable infusion reactions, diarrhea, fatigue, and nausea; minimal cardiac toxicity and no grade 4/5 TRAEs or treatment-related deaths.
No unexpected toxicities observed; regimen was chemotherapy-free and consistent with prior experience.
Clinical context and implications
Current post-T-DXd/Enhertu options are limited, often involving chemotherapy with significant toxicity and modest response rates.
The combination offers a non-chemotherapy alternative with promising efficacy and tolerability in a heavily pretreated population.
Higher HER2 expression correlated with better responses, supporting the mechanism of enhanced antibody-dependent phagocytosis.
Central HER2 confirmation is important due to tumor heterogeneity and evolving expression.
The study supports further development of evorpacept combinations in the post-T-DXd/Enhertu setting and potentially other HER2-expressing cancers.
Latest events from ALX Oncology
- Evorpacept advances in pivotal trials, extends cash runway, and prepares new ADC for the clinic.ALXO
Status Update9 Jul 2026 - Evorpacept plus PADCEV achieved a 59–62% response rate with favorable safety in advanced bladder cancer.ALXO
Study Update8 Jul 2026 - Two high-value oncology programs advance toward pivotal data with strong financial support.ALXO
Jefferies London Healthcare Conference 20258 Jul 2026 - First randomized CD47 solid tumor trial shows strong efficacy, fueling expansion and partnership talks.ALXO
2024 Cantor Fitzgerald Global Healthcare Conference8 Jul 2026 - All voting proposals passed and clinical programs advanced, with key data expected soon.ALXO
AGM 202610 Jun 2026 - Evorpacept and ALX2004 advance with strong data, robust funding, and pivotal trials planned.ALXO
Jefferies Global Healthcare Conference 20263 Jun 2026 - 100% response in CD47-high, HER2+ breast cancer; $169.1M cash supports 2026–2027 milestones.ALXO
Q1 202614 May 2026 - Virtual meeting to vote on directors, executive pay, and auditor, with strong governance oversight.ALXO
Proxy filing20 Apr 2026 - Evorpacept and ALX2004 advance with strong data, new biomarkers, and pivotal trials ahead.ALXO
TD Cowen 46th Annual Health Care Conference3 Mar 2026